baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Morgan Stanley Knock-Out BPMC/ DE000MG2J0U3 /

2024-09-17 9:57:26 PM	Chg.+0.05	Bid10:00:36 PM	Ask10:00:36 PM	Underlying	Strike price	Expiration date	Option type
1.31EUR	+3.97%	- Bid Size: -	- Ask Size: -	Blueprint Medicines ...	72.9849 USD	2078-12-31	Call

GlobeNewswire 08-05 Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024

GlobeNewswire 05-27 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medi...

GlobeNewswire 05-23 BPMC INVESTOR ALERT: Andrews & Springer LLC Investigates Blueprint Medicines Corporation

GlobeNewswire 05-20 BPMC Alert: The Law Firm of Andrews & Springer LLC Is Investigating Blueprint Medicines Corporation ...

GlobeNewswire 05-17 Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and ...

GlobeNewswire 05-14 Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...

GlobeNewswire 05-09 Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire 05-02 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...

GlobeNewswire 04-23 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...

GlobeNewswire 03-11 FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

GlobeNewswire 03-06 Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

GlobeNewswire 02-28 Recludix Pharma to Participate in Two Investor Conferences in March

GlobeNewswire 02-06 Recludix Pharma to Present at Two Investor Conferences in February

GlobeNewswire 01-17 Day One Announces Two New Appointments to Board of Directors

GlobeNewswire 2023-11-15 T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to tr...

GlobeNewswire 2023-11-09 Recludix Pharma to Present at Two Investor Conferences in November

GlobeNewswire 2023-10-31 Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile...

GlobeNewswire 2023-10-17 Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conf...

GlobeNewswire 2023-08-30 Recludix Pharma to Participate in Multiple Investor Conferences in September

GlobeNewswire 2023-08-29 Better Life Partners Raises $26.5 Million in Series B Financing to Amplify and Scale its Hybrid Whol...

GlobeNewswire 2022-03-10 Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update...

GlobeNewswire 2022-03-01 Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021

GlobeNewswire 2022-01-18 Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.

GlobeNewswire 2022-01-10 Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Caus...

GlobeNewswire 2022-01-06 Recludix Pharma Announces Scientific Advisory Board

Morgan Stanley Knock-Out BPMC/ DE000MG2J0U3 /

If you wish to receive reply to your feedback, please provide your email address.